Sold by: Next Move Strategy Consulting
Deployed on AWS
In Vivo CRO services support pharmaceutical research by conducting in vivo studies on animals to evaluate drug safety efficacy and pharmacokinetics. The market is expected to grow to 10.96 billion USD by 2030 at a compound annual growth rate of 9 percent from 2025 onward fueled by rising chronic diseases and healthcare advancements.
Overview
The global In Vivo CRO market centers on outsourced preclinical research services that utilize live animal models for drug development and disease modeling. This sector employs advanced imaging technologies like PET MRI and optical imaging to observe biological processes in real time. Driven by demands for precision medicine and faster drug discovery the market addresses needs in chronic disease therapies. Key influences include increasing chronic illnesses healthcare expansion in emerging areas and a growing elderly population. Challenges arise from high costs of infrastructure and operations yet opportunities emerge through AI integration and molecular imaging for better accuracy.
Request for a FREE Sample PDF Report: https://www.nextmsc.com/in-vivo-cro-market-hc3443/request-sample
The market overview highlights a focus on non invasive techniques that enhance translational research from animal models to human applications. With the global cancer incidence projected to rise from 20 million cases in 2022 to 35 million by 2050 according to World Health Organization data this drives demand for effective preclinical testing. Cardiovascular and neurodegenerative disorders also contribute significantly due to lifestyle factors and demographic shifts. In regions like India the healthcare sector valued at 372 billion USD in fiscal year 2023 employs 7.5 million people and anticipates 2.7 to 3.5 million new jobs in AI diagnostics and telemedicine supporting further research needs.
Growth drivers are multifaceted. The expansion of the geriatric population from 10 percent aged 65 and above in 2022 to 16 percent by 2050 per United Nations projections intensifies focus on age related conditions such as cancer arthritis and Alzheimer disease. These require sophisticated in vivo imaging for drug assessment. Additionally healthcare industry growth particularly in Asia Pacific with older persons increasing from 630 million in 2020 to 1.3 billion by 2050 per Economic and Social Commission for Asia and the Pacific boosts outsourcing of studies. This regional dynamic especially in China India Japan and South Korea benefits from infrastructure investments.
Restraints include substantial expenses for advanced equipment like PET SPECT and high resolution MRI which demand heavy investments in facilities maintenance and skilled staff. Regulatory compliance and safety protocols add to these burdens particularly challenging smaller contract research organizations in price sensitive markets. Despite this the integration of artificial intelligence with molecular imaging presents strong opportunities. AI improves image analysis for quicker disease detection and therapy evaluation while molecular probes allow real time views of cellular activities aiding precision medicine biomarker identification and diagnostics in oncology and neurology.
Market segmentation provides detailed insights. By model type it divides into rodents encompassing rat models mice models and other rodents alongside non rodents. Service offerings include contract research services such as pharmacology studies toxicology studies safety pharmacology and ADME toxicity efficacy and disease models pharmacokinetics and pharmacodynamics immunogenicity and biomarker assays. Equipment and reagents cover imaging systems like MRI PET and CT implantables and telemetry cages feed disposables tracers dyes antibodies and others. Animal models and strains feature wild type transgenic knock out knock in and disease specific variants. Software and analytics encompass in vivo data processing platforms modeling and simulation tools and AI machine learning driven analytics.
Inquire Before Buying: https://www.nextmsc.com/in-vivo-cro-market-hc3443/inquire-before-buying
Further segmentation by modality distinguishes small molecules from large molecules including cell and gene therapies like CAR T cell therapies CAR NK cell therapies TCR T cell therapies RNA therapies and other biologics. GLP compliance splits into GLP toxicology either in house or outsourced and non GLP similarly structured. Indications range from oncology central nervous system disorders autoimmune and inflammation pain management metabolic disorders to other areas. End users comprise pharmaceutical and biotechnology companies academic and research institutes contract research organizations hospitals and clinical centers and agrochemical and animal nutrition firms.
Regional analysis underscores North Americas dominance due to widespread adoption of minimally invasive methods robust research and development infrastructure and collaborative partnerships in preclinical imaging. This leadership persists through 2030. Europe experiences steady advancement from aging demographics and chronic disease burdens with strengths in neurology oncology and cardiovascular studies through academic and public private initiatives. Asia Pacific holds high growth potential driven by rapid population aging and cancer surges for instance India seeing cases rise from 26.7 million in 2021 to 29.8 million by 2025. The rest of the world including Latin America the Middle East and Africa shows gradual progress via improved healthcare access awareness of non communicable diseases and economical outsourcing options.
Access Full Report: https://www.nextmsc.com/report/in-vivo-cro-market-hc3443
Key players in the competitive landscape include Charles River Laboratories Crown Bioscience WuXi AppTec Eurofins Scientific ICON plc IQVIA Thermo Fisher Scientific Parexel Medpace Evotec Biomere JOINN Laboratories Taconic Biosciences SNBL and Pharmaron. Strategies emphasize expansions and innovations. For example Thermo Fishers June 2025 launch of the Tufts Accelerator CRO CDM O platform accelerates oncology drug development by up to three years with integrated in vivo testing. CRADLs June 2024 opening of a new site in Somerville Massachusetts enhances preclinical capabilities. Crown Biosciences March 2024 presentations at the American Association for Cancer Research showcase patient derived xenografts and tumor organoids for drug assessment. ICONs February 2024 acquisition of ClinicalRM strengthens expertise in vaccines and infectious diseases via in vivo models.
The report offers comprehensive analysis covering 2024 to 2030 with 2024 as the base year across 28 countries and market sizing in USD billions. It delivers quantitative trends investment opportunities impacts of drivers restraints and opportunities alongside in depth segmentation. Technologies featured include MRI PET CT and optical imaging with molecular probes for monitoring in toxicology pharmacokinetics efficacy testing and disease modeling. Primary end users are pharmaceutical and biotech firms medical device companies and academic institutions benefiting from these advanced services.
Contact Us:
Next Move Strategy Consulting
E-Mail: info@nextmsc.com
Direct: +18577585017
Website: https://www.nextmsc.com/
Details
Delivery method
Deployed on AWS
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
This product is available free of charge. Free subscriptions have no end date and may be canceled any time.
Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator to estimate your infrastructure costs.
Vendor refund policy
All sales are final; no refunds or returns are accepted. Our reports include sensitive, researched data from various sources, including industry experts and paid services. We ensure confidentiality and offer customization at an additional cost. Please review our terms before purchase. For inquiries, contact customer service.
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
NMSC_MarketResearch | All historical revisions | All future revisions | Not included | Not included |